Navigation Links
Bioassociate Announces Initiation of Coverage on KaloBios Pharmaceuticals, Inc.
Date:2/27/2013

TEL AVIV, Israel, February 27, 2013 /PRNewswire/ --

Bioassociate has initiated coverage on KaloBios Pharmaceuticals, Inc. (NASDAQ: KBIO).  The Initiation Report contains a detailed discussion of KaloBios' business operations, market dynamics, macroeconomic data and indicators, financial results, potential cash flows, and risks.  The Initiation Report is available at: http://www.bioassociate.com/research-and-publications/publications/.

Dr. Ofir Levi , Bioassociate's CEO: "KaloBios is developing monoclonal antibody (mAb) therapeutics based on the company's proprietary Humaneered™ antibody technology platform, with focus on respiratory related indications. KaloBios' lead program, KB001-A has been licensed by Sanofi Pasteur in 2010 for the treatment of Pseudomonas aeruginosa-related hospital-acquired infections.  The total deal value of this licensing agreement is $290 million plus royalties, including a $35 million upfront payment.  KaloBios recently completed an initial public offering and is now trading on the Nasdaq Global Market.  

 We see great potential in KaloBios' technology platform and clinical development programs. Further clinical development advancements are likely to attract additional potential collaborators, which will increase investors' attention.  For these reasons we, at Bioassociate, decided to initiate analysis coverage with a target price of $10.1 per share, which reflects an upside of 47% over the current share price.

About Bioassociate

Bioassociate is an independent investment research firm specialized in the life-science sector.  Bioassociate helps inform readers about small-mid cap life science companies without extensive analyst coverage.  Bioassociate structures its teams with multidisciplinary members to conduct specific assignments.  The Bioassociate team has industry experience as well as consulting and research track record, providing investors with in-depth scientific insights and their financial manifestation.

Disclosure: 

The research report described in this press release is not constructed as an offer to sell or the solicitation of an offer to buy any security in any jurisdiction where such an offer would be illegal.  Bioassociate is not soliciting any action based upon this material.  It does not take into account the particular investment objectives, financial situation, risk profile or other needs of individual investors.  Before acting on any advice or recommendation in this material, an investor should consider whether it is suitable for his/her particular circumstances and, if necessary, seek professional advice.  The report is based upon information that we consider reliable, but we do not represent that it is accurate or complete, and it should be relied upon as such.  Opinions expressed are Bioassociate's current opinions as of the date appearing on this material only; such opinions are subject to change without notice.  

Please read each report's full disclosures and analyst background on Bioassociate website, http://www.bioassociate.com, before investing.  Bioassociate is not a registered investment adviser or broker-dealer.

The research report described in this press release contains forward-looking data subject to risks and uncertainties that could cause actual results to differ materially from those projected.  These forward-looking data represent Bioassociate's judgment as of the date of this release.  Bioassociate disclaims, however, any intent or obligation to update this forward-looking data.

Contact:
info@bioassociae.com 
+972-3-541-5050


'/>"/>
SOURCE Bioassociate
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Precision Optics Corporation Announces $1 Million Order for Microprecision™ Based Endoscopes
2. Young Innovations, Inc. Announces Record Sales and EPS for the Quarter Ended March 31, 2012
3. JDRF Announces Research Collaboration with Dexcom, Inc. to Develop "Smart Transmitter" Technology to Accelerate Artificial Pancreas Studies
4. Misonix Announces New Distribution Agreement For Panama
5. University of Maryland BioPark Announces MedImmunes Dr. Bahija Jallal as Newest Member of Board of Directors for UM Health Sciences Research Park
6. Novelos Therapeutics Announces Successful Completion of First Cohort In Lung Cancer Trial With I-124-CLR1404 (LIGHT) Cancer-Targeted PET Imaging Agent at UW Carbone Cancer Center
7. Boston Scientific Announces CE Mark and European Launch of Emerge™ PTCA Dilatation Catheter
8. Soligenix Announces Further Progress with ThermoVax™ for Long-Term Vaccine ThermoStability
9. Masimo Announces New Low-Profile Infant and Neonatal Pulse Oximetry Sensors
10. Anthera Announces the Completion of Patient Dosing in Phase 2b PEARL-SC Study
11. STAAR Surgical Announces First Quarter 2012 Results Release Date and Conference Call and Webcast
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/12/2017)... , Sept. 12, 2017  ValGenesis Inc., the ... (VLMS), is pleased to announce the appointment of ... of its Board of Directors and Chairman of ... enables life science companies to manage their entire ... of paper in this process. Furthermore, ValGenesis VLMS ...
(Date:9/7/2017)... 2017  Eli Lilly and Company (NYSE: ... operations to more efficiently focus resources on developing ... Global workforce reductions, including those from a U.S. ... approximately 3,500 positions. With the ... of approximately $500 million that will begin to ...
(Date:9/7/2017)...  Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), ... it will be participating in the Morgan Stanley 15 ... Hyatt hotel in New York.  Zimmer Biomet will present ... Time. A live webcast of the presentation ... at http://investor.zimmerbiomet.com .   ...
Breaking Medicine Technology:
(Date:9/25/2017)... ... ... How many things are on your average daily to-do list? If your ... human could possibly complete,” then you’re all too familiar with daily chaos. You have ... everything to everybody all the time. , Self-proclaimed overly productive person Angela Nuttle knows ...
(Date:9/25/2017)... ... September 25, 2017 , ... NCPDP Foundation , ... it has awarded a $40,000 grant to Johns Hopkins Medicine to address patient ... enables prescribers to electronically cancel a prescription already submitted to a pharmacy. Studies ...
(Date:9/25/2017)... ... September 25, 2017 , ... ... nationally syndicated The Sharon Kleyne Hour Power of Water, Global Climate Change and ... shift our Olympic focus from a once-every-four-years series of events to a personal, ...
(Date:9/25/2017)... ... September 25, 2017 , ... Bobbie Horowitz was hardly able to ... health issues. As a cabaret and theater producer, Horowitz would manage to get to ... transportation in New York City, so she had to take a cab everywhere. ...
(Date:9/25/2017)... ... September 25, 2017 , ... ... and technology-enabled services supporting clinical research, today announces that 30 of its ... of the drug development lifecycle at upcoming industry conferences and webinars. Drawing ...
Breaking Medicine News(10 mins):